Skip to main content
. 2021 Aug 24;12:723566. doi: 10.3389/fimmu.2021.723566

Figure 2.

Figure 2

Phosphopeptides identified from colorectal cancer samples – putative cancer antigens. (A) Comparison of phosphopeptides identified on tumors and healthy tissue from CRC patients with primary (n=3) and secondary (n=2) tumors and CRC cell lines (n=3). (B) Proportion of the phosphopeptides identified on primary and secondary tumors that were healthy specific (not detected on tumor) (blue), healthy associated (more detected on healthy than tumor tissue) (purple), equal (where equal was within one order of magnitude) (green), tumor associated (more detected on tumor than healthy tissue) (orange) and tumor specific (not detected on healthy tissue) (red). (C) The number of phosphopeptides identified predicted to bind to different HLA-I. Pie charts show the proportion of phosphopeptides shared (red) across multiple patients’ samples for the most common HLA-alleles. (D) Overlap of HLA-A*02 and HLA-B*07 phosphopeptides identified on CRC (pink) with those found on other types of malignancy; melanoma (blue) and leukemia (yellow).